A new article published in the International Journal of Women’s Health discussed that vulvovaginal atrophy (VVA) is a silent epidemic that affects up to 50-60% of postmenopausal women and is usually not reported. Hormonal changes – hypoestrogenism, during menopause, leads to the development of VVA. The authors reported that more than half of menopausal women suffer from symptoms of VVA, such as dryness, burning, itching, vaginal discomfort, pain and burning while urinating, dyspareunia, and spotting during intercourse. All these manifestations significantly reduce the quality of life of women post menopause and cause discomfort in the sexual sphere. However, only 25% of patients with the symptoms of VVA receive adequate therapy. The reasons being, a majority of the patients hesitate in discussing intimate complaints with a specialist which makes it difficult to verify the diagnosis while some regard symptoms of VVA as manifestations of the natural aging process and do not seek help. Owing to recent drug developments, various options now exist for treating this pathological condition, including systemic and topical hormone replacement therapy, selective estrogen receptor modulators, vaginal dehydroepiandrosterone, use of lubricants and moisturizers, as well as non-pharmaceutical therapies. In inference, it was stated that a timely diagnosis and adequately selected therapy for the main symptoms of VVA can help in restoration and maintenance of the vaginal function and vaginal health in women, post menopause.